© 2019 Hylomorph AG

Hylomate is a registered trademark - all rights reserved

Privacy Policy

  • LinkedIn Social Icon

CUTTING EDGE SCIENCE

ABOUT

Hylomorph is an innovative Medtech company engineering biomaterials to optimize the interface between implantable medical devices and tissues.

 

Our goal is to transform the biocompatibility of implantable medical devices to improve the quality of life of patients and the quality of care by healthcare professionals, while reducing overall healthcare costs.

The proprietary CellSense technology was developed in the cutting-edge laboratories of the Swiss Federal Institute of Technology (ETH Zurich). Hylomorph's first product, Hylomate, has demonstrated outstanding performance in reducing foreign body reaction and fibrotic buildup in pre-clinical settings and preparations are currently being made for first-in-man clinical trials in Germany.

TEAM

  • LinkedIn Social Icon
Simone Bottan

CHIEF EXECUTIVE OFFICER

  • LinkedIn Social Icon
Francesco Robotti

CHIEF OPERATING OFFICER

  • LinkedIn Social Icon
Aldo Ferrari

CHIEF TECHNICAL OFFICER

  • LinkedIn Social Icon
Sonia Schmocker

CHIEF REGULATORY AND QUALITY OFFICER

  • LinkedIn Social Icon
Peter Jackson

CHIEF COMMERCIAL OFFICER

  • LinkedIn Social Icon
Sebastian Cavalli

QUALITY SPECIALIST

BOARD OF DIRECTORS

  • LinkedIn Social Icon
Gian-Luigi Berini

BOARD CHAIR

  • LinkedIn Social Icon
Simone Bottan

CHIEF EXECUTIVE OFFICER

  • LinkedIn Social Icon
Peter Gabriel

BOARD MEMBER

  • LinkedIn Social Icon
Aldo Ferrari

CHIEF TECHNICAL OFFICER